An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC.
Vuong L, et al. Among authors: sethi t.
Cancer Res. 2019 Apr 1;79(7):1480-1492. doi: 10.1158/0008-5472.CAN-18-2244. Epub 2019 Jan 23.
Cancer Res. 2019.
PMID: 30674531